Lanean...

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

PURPOSE: Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy. However, there are conflicting findings regarding the potential benefit of adjuvant EGFR-TKI in patients with lung cancer harboring E...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Oxnard, Geoffrey R., Janjigian, Yelena Y., Arcila, Maria E., Sima, Camelia S., Kass, Samantha L., Riely, Gregory J., Pao, William, Kris, Mark G., Ladanyi, Marc, Azzoli, Christopher G., Miller, Vincent A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186869/
https://ncbi.nlm.nih.gov/pubmed/21831955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1080
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!